- Home
- KF vs AGEN Comparison
KF vs AGEN Comparison
Compare KF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- AGEN
- Stock Information
- Founded
- KF 1984
- AGEN 1994
- Country
- KF United States
- AGEN United States
- Employees
- KF N/A
- AGEN N/A
- Industry
- KF Investment Managers
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KF Finance
- AGEN Health Care
- Exchange
- KF Nasdaq
- AGEN Nasdaq
- Market Cap
- KF 98.6M
- AGEN 96.2M
- IPO Year
- KF N/A
- AGEN 2000
- Fundamental
- Price
- KF $19.79
- AGEN $1.48
- Analyst Decision
- KF
- AGEN Buy
- Analyst Count
- KF 0
- AGEN 4
- Target Price
- KF N/A
- AGEN $8.00
- AVG Volume (30 Days)
- KF 18.4K
- AGEN 488.3K
- Earning Date
- KF 01-01-0001
- AGEN 03-11-2025
- Dividend Yield
- KF N/A
- AGEN N/A
- EPS Growth
- KF N/A
- AGEN N/A
- EPS
- KF N/A
- AGEN N/A
- Revenue
- KF N/A
- AGEN $103,463,000.00
- Revenue This Year
- KF N/A
- AGEN $32.21
- Revenue Next Year
- KF N/A
- AGEN N/A
- P/E Ratio
- KF N/A
- AGEN N/A
- Revenue Growth
- KF N/A
- AGEN N/A
- 52 Week Low
- KF $18.30
- AGEN $1.55
- 52 Week High
- KF $25.56
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- KF 35.47
- AGEN 23.91
- Support Level
- KF $20.93
- AGEN $1.55
- Resistance Level
- KF $21.29
- AGEN $1.77
- Average True Range (ATR)
- KF 0.37
- AGEN 0.16
- MACD
- KF -0.12
- AGEN 0.02
- Stochastic Oscillator
- KF 1.98
- AGEN 6.76
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).